Ratings Alembic Pharmaceuticals Limited

Equities

APLLTD

INE901L01018

Delayed NSE India S.E. Other stock markets 06:41:22 30/04/2024 BST			5-day change	1st Jan Change
997.7 ^INR	+0.09%		+6.11%	+31.38%

04-26	Alembic Pharmaceuticals Limited Receives Order from the Office of Deputy Commissioner (ST), Guwahati, Assam	CI
04-18	Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

With an expected P/E ratio at 32.77 and 27.56 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
ALEMBIC PHARMACEUTICALS LIMITED	+31.38%	2.35B	C+
ELI LILLY AND COMPANY	+26.47%	664B	C+
NOVO NORDISK A/S	+26.74%	567B	B
JOHNSON & JOHNSON	-6.33%	354B	C+
MERCK & CO., INC.	+19.35%	330B	B-
ABBVIE INC.	+4.23%	286B	C+
ASTRAZENECA PLC	+13.43%	234B	B+
NOVARTIS AG	+4.71%	199B	B-
ROCHE HOLDING AG	-9.53%	196B	A+
AMGEN INC.	-4.04%	148B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes